GlassScriptPhysician profile
Phillip A Musikanth
NPI 1760495741
$11,253.92
in general payments reported to CMS, 2019-2025
37 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,403 · 2020: $927 · 2021: $1,902 · 2022: $1,876 · 2023: $2,322 · 2024: $1,556 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,146.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,967.01 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $2,290.72 | 2019-2025 | |
| Emd Serono, INC. | $799.51 | 2019-2024 | Serostim |
| Janssen Biotech, INC. | $710.25 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $483.16 | 2019-2023 | Mytesi |
| Abbvie INC. | $468.35 | 2019-2025 | |
| Amgen INC. | $383.96 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.59 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $237.01 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $217.35 | 2019-2023 | Egrifta, Trogarzo |
| Antares Pharma, INC. | $208.14 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Bausch Health US, LLC | $153.75 | 2021-2025 | Aplenzin |
| Amarin Pharma, INC. | $127.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $124.08 | 2019-2025 | Arexvy, Shingrix |
| Pfizer INC. | $89.65 | 2020-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Musikanth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.